ReviewPharmacoEconomics - open2021

A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-small Cell Lung Cancer.

Nan Qiao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.